On December 12, 2018, the Board of Directors of Achillion Pharmaceuticals, Inc. appointed Keri Lantz, on an interim basis, to the positions of principal financial officer and principal accounting officer, effective as of January 1, 2019. This appointment is being made in connection with the departure of Mary Kay Fenton, the company's current Chief Financial Officer, whose resignation was previously announced and is effective as of December 28, 2018. Ms. Lantz has served as the company's Corporate Controller and Vice President of Finance since January 2017.

From January 2014 to December 2016, Ms. Lantz served as the company's Corporate Controller and Executive Director, Financial Reporting and from January 2011 to December 2013 as the company's Corporate Controller and Senior Director, Financial Reporting.